Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    evonik-m-2025-09-08

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Menu

    Ocrelizumab

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 3Gowling WLG (Canada) LLP

    filter clear-filterReset all filters

    filter clear-filterReset all filters

    filter clear-filterReset all filters

    filter clear-filterReset all filters

    PharmaCompass
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Gowling WLG (Canada) LLP

    OCRELIZUMAB
    arrow
    ECRM CMO & Packaging
    Not Confirmed

    Gowling WLG (Canada) LLP

    Country
    arrow
    ECRM CMO & Packaging
    Not Confirmed

    Patent Expiration Date : 2018-06-12

    Date Granted : 2008-09-16

    OCRELIZUMAB

    Brand Name : OCREVUS

    Patent Number : 2292730

    Filing Date : 1998-06-12

    Strength per Unit : 30mg / mL

    Dosage Form : SOLUTION

    Human Or VET : Human

    Route of Administration : INTRAVENOUS

    Patent Expiration Date : 2018-06-12

    Date Granted : 2008-09-16

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Gowling WLG (Canada) LLP

    OCRELIZUMAB
    arrow
    ECRM CMO & Packaging
    Not Confirmed

    Gowling WLG (Canada) LLP

    Country
    arrow
    ECRM CMO & Packaging
    Not Confirmed

    Patent Expiration Date : 2023-12-16

    Date Granted : 2014-02-18

    OCRELIZUMAB

    Brand Name : OCREVUS

    Patent Number : 2507898

    Filing Date : 2003-12-16

    Strength per Unit : 30mg / mL

    Dosage Form : SOLUTION

    Human Or VET : Human

    Route of Administration : INTRAVENOUS

    Patent Expiration Date : 2023-12-16

    Date Granted : 2014-02-18

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Gowling WLG (Canada) LLP

    OCRELIZUMAB
    arrow
    ECRM CMO & Packaging
    Not Confirmed

    Gowling WLG (Canada) LLP

    Country
    arrow
    ECRM CMO & Packaging
    Not Confirmed

    Patent Expiration Date : 2029-09-16

    Date Granted : 2021-04-13

    OCRELIZUMAB

    Brand Name : OCREVUS

    Patent Number : 2737074

    Filing Date : 2009-09-16

    Strength per Unit : 30mg / mL

    Dosage Form : SOLUTION

    Human Or VET : Human

    Route of Administration : INTRAVENOUS

    Patent Expiration Date : 2029-09-16

    Date Granted : 2021-04-13

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF